BlackRock Group’s Esperion Therapeutics ESPR Stock Holding History

BlackRock Group’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$72K	Buy	5,811 +504	+9%	+$6K	﹤0.01%	2878
2016 Q3	$74K	Sell	5,307 -88	-2%	-$997	﹤0.01%	2863
2016 Q2	$52K	Sell	5,395 -72	-1%	-$1.19K	﹤0.01%	2907
2016 Q1	$93K	Buy	5,467 +1,617	+42%	+$26K	﹤0.01%	2785
2015 Q4	$86K	Sell	3,850 -96	-2%	-$2.42K	﹤0.01%	2728
2015 Q3	$93K	Buy	3,946 +802	+26%	+$50.3K	﹤0.01%	2723
2015 Q2	$257K	Buy	3,144 +1,535	+95%	+$150K	﹤0.01%	2512
2015 Q1	$149K	Buy	+1,609	New	+$104K	﹤0.01%	2569
2013 Q4	–	Sell	-32,044	Closed	-$604K	–	2702
2013 Q3	$604K	Buy	+32,044	New	+$538K	﹤0.01%	2150

Other funds holding ESPR

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock Group's ESPR Position: Q4 2016 in Review

BlackRock Group increased its Esperion Therapeutics (ESPR) stake by 9.5% in Q4 2016, buying an estimated $6K and bringing the position to 5,811 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #2878.

BlackRock Group first reported a position in ESPR in Q3 2013 and has held it in 9 quarters since. The position peaked at $604K in Q3 2013. 99 funds tracked by Wall St. Rank hold ESPR as of Q4 2016.

BlackRock Group held 5,811 shares of Esperion Therapeutics worth $72K as of Q4 2016.
BlackRock Group bought 504 Esperion Therapeutics shares in Q4 2016, an estimated $6K.
Esperion Therapeutics made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2878 holding.
BlackRock Group first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 9 quarters since.
BlackRock Group's Esperion Therapeutics position peaked at $604K in Q3 2013.
99 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.